Resource Center

Explore our library of helpful resources and scientific content on GP-2250.

Resource Center Photo

Filter by Resource Type

  • Press Releases
  • Publications
  • Brochures
  • Videos
  • Events
Press Release – February 1, 2024

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

 
publication

Antineoplastic activity of GP-2250 in-vitro and in mouse xenograft models

R. Duane Sofia, Kathryn M. Martin and James C. Costin

 
Press Release – November 21, 2023

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

 
publication

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

Thilo Gambichler , Friederike Harnischfeger , Marina Skrygan , Britta Majchrzak-Stiller , Marie Buchholz , Thomas Müller and Chris Braumann

 
Press Release – October 5, 2023

Panavance to Present at the BIO Investor Forum

 
Press Release – September 12, 2023

Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer

 
publication

GP- 2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP- Kinase and impairs the NF- kB pathway in pancreatic cancer cells

Britta Majchrzak- Stiller, Marie Buchholz, Ilka Peters, Daniel Waschestjuk, Johanna Strotmann, Philipp Höhn, Stephan Hahn, Chris Braumann, Waldemar Uhl, Thomas Müller, Hanns Möhler

 
publication

The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results

Thilo Gambichler, Britta Majchrzak-Stiller, Ilka Peters, Jürgen C Becker, Johanna Strotmann, Nessr Abu Rached, Thomas Müller, Waldemar Uhl 2, Marie Buchholz, Chris Braumann

 
event

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast on Thursday, July 13th at 2:00 PM ET

Jtc Vi Pana Logo
 
Press Release – July 5, 2023

Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series

 
Press Release – June 29, 2023

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Merkel Cell Carcinoma (MCC)

 
publication

Substance GP-2250 as a new therapeutic agent for malignant peritoneal mesothelioma – a 3-D in vitro study

Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann and Chris Braumann

 
publication

An In Vitro Pilot Study Investigating the Antineoplastic Effects of GP-2250 on Cutaneous Squamous Cell Carcinoma Cell Lines: Preliminary Results

Milan Barras, Lutz Schmitz, Chris Braumann, Waldemar Uhl, Marina Skrygan, Marie Buchholz, Thomas Meyer, Eggert Stockfleth, Thomas Müller, Jürgen C. Becker and Thilo Gambichler

 
publication

Oxathiazinane Derivatives Display Both Anticancer and Antibacterial Activity: A Structure Activity Study

B. Majchrzak Stiller, M. Buchholz, I. Peters, J. Strotmann, J. Möhrke, L. Zelichowski, L. Oehlke, C. Quensel, D. Fein, P. Höhn, T. Müller, W. Uhl, C. Braumann May 12, 2023

 
Press Release – May 24, 2023

Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention

 
publication

Mechanisms and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer

American Association for Cancer Research (AACR) Annual Meeting 2023

Mark S. Kim, Deanna Glassman, Adrian Lankenau Ahumada, Emine Bayraktar, Nicholas B. Jennings, Robiya Joseph, Sanghoon Lee, Robert L. Coleman, Anil K. Sood

 
Press Release – April 17, 2023

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating GP-2250 Single-Agent and Combination Activity for the Treatment of Ovarian Cancer

 
Press Release – April 12, 2023

Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference

 
Press Release – March 20, 2023

Panavance Therapeutics Announces Acceptance of Abstract to be Presented at
the American Association for Cancer Research (AACR) Annual Meeting 2023

 
event

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Wednesday, January 18th at 1:00 PM ET

Jtc Vi Pana Logo
 
Press Release – January 5, 2023

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

 
event

Panavance Leadership Team participation in the Virtual Investor Innovations in Oncology Event

Greg Bosch, Chairman and CEO of Panavance Therapeutics along with other members of the Panavance Leadership Team participated in the Virtual Investor Innovations in Oncology Spotlight Event. As part of the virtual roundtable event, the Company discussed its lead program, GP-2250, a tumor cell selective and broadly active small molecule with a unique mechanism of action designed to disrupt energy metabolism, resulting in cancer cell death.

Jtc Vi Pana Logo
 
Press Release – December 5, 2022

Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event

 
Press Release – November 14, 2022

Panavance Therapeutics to Present at the Pharma Partnering US Summit 2022

 
Press Release – November 2, 2022

Panavance Therapeutics to Present at BioFuture 2022

 
Press Release – August 8, 2022

Panavance Therapeutics Announces Publication of Promising Preclinical Data Evaluating GP-2250 for the Treatment of Malignant Peritoneal Mesothelioma

 
Press Release – June 28, 2022

Panavance Therapeutics Announces Orphan Drug Designation for GP-2250 for the Treatment of Pancreatic Cancer

 
publication

New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo

Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller, Stephan Hahn 2, Ilka Peters, Julian Horn Thomas Müller, Philipp Höhn, Waldemar Uhl and Chris Braumann

 
Press Release – June 9, 2022

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 for the Treatment of Pancreatic Neuroendocrine Carcinoma

 
video

Mechanism of Action Explainer Video

While cancer therapies are becoming increasingly specific to tumor and mutation type, a tumor and mutation agnostic yet targeted agent is of high therapeutic utility. Learn about GP-2250’s unique mechanism of action, which kills cancer cells by disrupting their energy metabolism.

Method Of Action Explainer Video
 
brochure

New hope begins with novel science.

Panavance’s purpose is to give every patient the best possible chance to live a healthy and cancer-free life.

Panavance Novel Science Brochure
 
publication

Innovative substance 2250, a derivative of taurultam, shows anti-neoplastic effects in malignant pancreatic carcinoma in vitro and in vivo

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, R.W. Pfirrmann, A.M. Chromik, W. Uhl.

 
publication

Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo.

M. Buchholz, B. Majchrzak-Stiller, S. Hahn, D. Vangala, R. W. Pfirrmann, W. Uhl, C. Braumann and A. M. Chromik.

 
publication

Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer

C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.)

 
publication

A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of GP-2250 in combination with gemcitabine for advanced or metastatic pancreatic adenocarcinoma.

A. Kasi, J. L. Iglesias.

 
Press Release – January 19, 2022

Panavance Announces Abstract and Poster at ASCO Gastrointestinal Cancers Symposium, Providing an Update on the Status of GP-2250 Clinical Trial in Pancreatic Cancer Patients